Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
3.370
-0.010 (-0.29%)
At close: Jun 26, 2026, 4:00 PM EDT
3.360
-0.010 (-0.30%)
After-hours: Jun 26, 2026, 4:10 PM EDT
Lisata Therapeutics Revenue
Lisata Therapeutics had revenue of $170.00K in the twelve months ending March 31, 2026. In the year 2025, Lisata Therapeutics had annual revenue of $170.00K, down -83.00%.
Revenue (ttm)
$170.00K
Revenue Growth
-83.00%
P/S Ratio
179.99
Revenue / Employee
$8,095
Employees
21
Market Cap
30.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.00K | -830.00K | -83.00% |
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 22.49M | 4.55M | 25.36% |
| Dec 31, 2014 | 17.94M | 3.27M | 22.29% |
| Dec 31, 2013 | 14.67M | 338.60K | 2.36% |
| Dec 31, 2012 | 14.33M | 4.28M | 42.58% |
| Dec 31, 2011 | 10.05M | -59.77M | -85.61% |
| Dec 31, 2010 | 69.82M | 58.26M | 503.72% |
| Dec 31, 2009 | 11.57M | 11.48M | 13,743.62% |
| Dec 31, 2008 | 83.54K | -148.12K | -63.94% |
| Dec 31, 2007 | 231.66K | 185.94K | 406.66% |
| Dec 31, 2006 | 45.72K | 10.46K | 29.67% |
| Dec 31, 2005 | 35.26K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Barinthus Biotherapeutics | 14.97M |
| Kyntra Bio | 7.44M |
| Plus Therapeutics | 5.18M |
| Dyadic International | 3.81M |
| Vistagen Therapeutics | 1.27M |
| Daré Bioscience | 1.16M |
| Actinium Pharmaceuticals | 90.00K |
LSTA News
- 15 hours ago - Johnson Fistel Investigates Lisata Therapeutics, Inc. (LSTA) After Disclosures Concerning Acquisition Financing - GlobeNewsWire
- 11 days ago - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Lisata Therapeutics, Inc. (LSTA) - Newsfile Corp
- 16 days ago - Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc. - GlobeNewsWire
- 6 weeks ago - Lisata Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 6 weeks ago - Lisata Therapeutics Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders - GlobeNewsWire
- 3 months ago - Lisata Therapeutics Annual report: Q4 2025 - Filings
- 4 months ago - Lisata Therapeutics to be acquired by Kuva Labs for $5 per share cash plus CVR - TheFly